Aeras

Web tool highlights ongoing impact of tuberculosis in the United States

ROCKVILLE, MD – March 24, 2014 -- The tuberculosis epidemic continues to impact pockets of the U.S. population, according to a data visualization tool developed by the nonprofit biotech, Aeras. Launched on World TB Day, Aeras’s TB Crisis Tracker illustrates how the TB epidemic continues to impact the U.S.

Read More →

Film highlights TB epidemic in China and China’s crucial role in eliminating TB worldwide

March 21, 2014 – Beijing, China - A short documentary film exploring the tuberculosis (TB) epidemic in China has been launched by Aeras, a nonprofit biotech advancing tuberculosis vaccines for the world. “Hope: Developing Safe and Effective Vaccines to Fight TB” highlights China’s desire and innovative leadership in solving the global problem of TB. The film includes Chinese researchers who are leading the way in developing new vaccines to prevent tuberculosis. Featuring patients, doctors and top TB vaccine researchers, Hope illuminates China’s unique role in ending the global tuberculosis epidemic.

Read More →

Dartmouth and Aeras join forces to conduct study of new tuberculosis vaccine

Hanover, NH and Rockville, MD, March 19, 2014 – Dartmouth’s Geisel School of Medicine and Aeras, a global nonprofit biotech, announced a collaboration to jointly conduct a trial of a new vaccine against tuberculosis (TB), one of the world’s deadliest diseases. The vaccine, known as DAR-901, is related to the vaccine SRL-172, previously shown by Dartmouth investigators to decrease the risk of TB in a trial known as the DarDar Trial.

Read More →

Novel vaccine trial design aims to answer key TB questions

Prevention of infection study underway in South Africa.

Read More →

Mining is fueling a global TB epidemic

Tell the Southern African Development Community nations to prioritize TB R&D. Sign the petition.

Read More →

Global collaboration forms to advance Japanese TB vaccine technology

January 27, 2014 – Osaka, Japan and Rockville, MD, USA - Japan’s National Institute of Biomedical Innovation(“NIBIO”), Aerasand Create Vaccine Company, Ltd(“CREATE”) announce today that they signed a collaboration agreementon December 26, 2013, on the preclinical and clinical development of new mucosal tuberculosis (TB) vaccines based on NIBIO’s human parainfluenza type-2 (rhPIV2) vector technology.

Read More →

Aeras: Annual report

Read More →

EXPOSED film series wins Best Cause-Related Video

October 14, 2013, ROCKVILLE, MD – Aeras has been awarded Best Cause-Related Video for its film series, EXPOSED: The Race Against Tuberculosis by PR Daily. The PR Daily Digital PR award winners include some of the most recognized names in public relations and communications from around the world. The EXPOSED series also won an honorable mention under “Best Digital PR Campaign – Nonprofit Sector.”

Read More →

Aeras: EXPOSED: The Race Against Tuberculosis - films series now available in 7 languages

Watch the four-part series of short films on the deadly global TB epidemic and the race to develop new tools to prevent it, now with subtitles in seven languages: http://www.aeras.org/exposed

Read More →

AusAID pledges AUS$2.5M “shot in the arm” to Aeras for TB vaccine R&D

ROCKVILLE, Md. (August 19, 2013)— The government of Australia has expanded its role in the global battle against tuberculosis, providing a grant of AUS$2.5 million to fund the quest for an effective vaccine against a silent killer that infects one out of three people worldwide.

Read More →

Page 2 of 4 · Total posts: 10

←First 1 2 3 Last→